Morgan Stanley Maintains Equal-Weight on 8×8, Lowers Price Target to $4

Morgan Stanley analyst Meta Marshall maintains 8×8 (NYSE:EGHT) with a Equal-Weight and lowers the price target from $6.5 to $4.

byBenzinga Newsdesk

October 11, 2022

1 minute read

Morgan Stanley analyst Meta Marshall maintains 8×8 (NYSE:EGHT) with a Equal-Weight and lowers the price target from $6.5 to $4.

Immutep Filing Shows Co. Received European Medicines Agency Advice For Further Clinical Development Of Efti In Metastatic Breast Cancer, Including Phase 3 Trial

By Benzinga Newsdesk

Today, 10:44 AM

Immutep receives positive EMA scientific advice for further clinical development of efti in MBC including Phase III • Positive feedback for the general clinical development

IMMP

Morgan Stanley Maintains Underweight on Range Resources, Lowers Price Target to $31

By Benzinga Newsdesk

Today, 10:44 AM

Morgan Stanley analyst Devin McDermott maintains Range Resources (NYSE:RRC) with a Underweight and lowers the price target from $32 to $31.

RRC

GSE Systems Q3 Sales $11.90M Down From $14.69M YoY

By Benzinga Newsdesk

Today, 10:44 AM

GSE Systems (NASDAQ:GVP) reported $11.90 million in sales this quarter. This is a 18.98 percent decrease over sales of $14.69 million the same period last year.

GVP

Why Should Cannabis Investors Pay Attention To Germany? These Stocks Will Benefit From Imminent Legalization

By Jelena Martinovic

Today, 10:44 AM

With US federal legalization stalled and its near-term outcome uncertain, cannabis stocks are taking a hit. Cantor Fitzgerald's analyst Pablo Zuanic advised investors to turn their interest to Germany, or at least for now.

ACB

Morgan Stanley Maintains Equal-Weight on 8×8, Lowers Price Target to $4

Related Posts

Immutep Filing Shows Co. Received European Medicines Agency Advice For Further Clinical Development Of Efti In Metastatic Breast Cancer, Including Phase 3 Trial

Morgan Stanley Maintains Underweight on Range Resources, Lowers Price Target to $31

GSE Systems Q3 Sales $11.90M Down From $14.69M YoY

Why Should Cannabis Investors Pay Attention To Germany? These Stocks Will Benefit From Imminent Legalization